Nurix Stock Valuation

NRIX
 Stock
  

USD 13.03  0.14  1.09%   

Do you wonder what the value of Nurix Therapeutics is? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Nurix Therapeutics, is its stock price multiplied by the total number of shares outstanding, calculating Nurix Therapeutics' enterprise value requires a different approach. It uses Nurix Therapeutics' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Nurix Therapeutics secures a last-minute Real Value of $22.15 per share. The latest price of the firm is $13.03. At this time, the firm appears to be undervalued. Our model forecasts the value of Nurix Therapeutics from analyzing the firm fundamentals such as Return On Equity of (46.46) %, operating margin of (401.56) %, and Shares Outstanding of 47.04 M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will merge together.
  
Nurix Therapeutics Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Nurix Therapeutics's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today 13.03
Please note that Nurix Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Nurix Therapeutics is based on 3 months time horizon. Increasing Nurix Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Nurix Therapeutics is useful when determining the fair value of the Nurix stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Nurix Therapeutics. Since Nurix Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nurix Stock. However, Nurix Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
22.15
Real Value
27.24
Upside
Estimating the potential upside or downside of Nurix Therapeutics helps investors to forecast how Nurix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nurix Therapeutics more accurately as focusing exclusively on Nurix Therapeutics' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
12.2915.2718.25
Details
Hype
Prediction
LowEstimated ValueHigh
7.9713.0618.15
Details
Naive
Forecast
LowNext ValueHigh
6.6811.7716.86
Details
6 Analysts
Consensus
LowTarget PriceHigh
42.0048.0060.00
Details

Nurix Therapeutics Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Nurix Therapeutics's current stock value. Our valuation model uses many indicators to compare Nurix Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nurix Therapeutics competition to find correlations between indicators driving Nurix Therapeutics's intrinsic value. More Info.
Nurix Therapeutics is considered to be number one stock in price to sales category among related companies. It is considered to be number one stock in price to book category among related companies fabricating about  0.14  of Price to Book per Price to Sales. The ratio of Price to Sales to Price to Book for Nurix Therapeutics is roughly  7.18 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nurix Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nurix Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nurix Therapeutics' earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Nurix Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Nurix Therapeutics and how it compares across the competition.

About Nurix Therapeutics Valuation

The stock valuation mechanism determines the current worth of Nurix Therapeutics on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Nurix Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Nurix Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Nurix Therapeutics's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Nurix Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nurix Therapeutics. We calculate exposure to Nurix Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Nurix Therapeutics's related companies.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company was incorporated in 2009 and is headquartered in San Francisco, California. Nurix Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.

Nurix Therapeutics Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Nurix Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio4.10
Revenue Growth61.20%
Enterprise Value To Ebitda-2.02
Enterprise Value To Revenue7.92
Additionally, see Correlation Analysis. You can also try Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Complementary Tools for analysis

When running Nurix Therapeutics price analysis, check to measure Nurix Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nurix Therapeutics is operating at the current time. Most of Nurix Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nurix Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nurix Therapeutics' price. Additionally, you may evaluate how the addition of Nurix Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Is Nurix Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nurix Therapeutics. If investors know Nurix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nurix Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Nurix Therapeutics is measured differently than its book value, which is the value of Nurix that is recorded on the company's balance sheet. Investors also form their own opinion of Nurix Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nurix Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nurix Therapeutics' market value can be influenced by many factors that don't directly affect Nurix Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nurix Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Nurix Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nurix Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.